Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: To screen or not to screen: an interactive framework for comparing costs of mass malaria treatment interventions

Fig. 2

Costs of mass drug administration (MDA) and mass screen and treat (MSAT) based on malaria prevalence. Each panel depicts a different scenario relative to the costs associated with false positive (FP) and false negative (FN) outcomes, as specified in the legends. The lower estimated cost (y-axis) indicates which strategy will have lower associated costs for a given prevalence rate (x-axis). RDT sensitivity and specificity ranged from 0.82 to 0.96 and 0.80 to 0.90, respectively, and the cost of treatment and RDT were set to $2.40 and $0.60, based on a WHO report [26]. The gray-shaded region indicates overlap in expected cost, where the more favorable strategy is unclear due to the range of possible values for RDT sensitivity and specificity

Back to article page